• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3

cafead

Administrator
Staff member
  • cafead   May 24, 2023 at 10:22: AM
via Shares of precision oncology company Rain Oncology (NASDAQ:RAIN) fell off a cliff Monday after its lead product candidate failed to meet the primary endpoint in a Phase 3 trial for the treatment of dedifferentiated liposarcoma (DD LPS).

article source
 

<